Suppr超能文献

4-1BB(CD137)受体与配体的生化及免疫学特性及其在癌症治疗中的潜在应用

Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.

作者信息

Sica G, Chen L

机构信息

Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905, USA.

出版信息

Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9.

Abstract

4-1BB (CD 137) is a member of the tumor necrosis factor receptor (TNFR) superfamily that is expressed primarily on activated T cells. Crosslinking of the 4-1BB receptor activates an intracellular signal cascade that leads to the activation of NF-kappaB and costimulation of T cell growth. Recent evidence indicates that 4-1BB may preferentially costimulate CD8+ T cell growth and induce cytolytic activity. The cytolytic activity induced by 4-1BB crosslinking is able to eradicate large, well-established, poorly immunogenic tumors and augments allogenic T cell responses in vivo. The 4-1BB/4-1BB ligand costimulatory pathway can provide an alternative T cell costimulatory pathway in the absence of CD28, but may physiologically function as a synergistic or complementary pathway to the CD28 costimulatory pathway. Only some of the basic immunological functions of 4-1BB/4-IBB ligand have been elucidated and much study is required to determine its exact role in T cell activation.

摘要

4-1BB(CD137)是肿瘤坏死因子受体(TNFR)超家族的成员,主要在活化的T细胞上表达。4-1BB受体的交联激活细胞内信号级联反应,导致核因子κB的激活和T细胞生长的共刺激。最近的证据表明,4-1BB可能优先共刺激CD8+T细胞生长并诱导细胞溶解活性。4-1BB交联诱导的细胞溶解活性能够根除大型、已形成且免疫原性差的肿瘤,并增强体内同种异体T细胞反应。在缺乏CD28的情况下,4-1BB/4-1BB配体共刺激途径可提供另一种T细胞共刺激途径,但在生理上可能作为CD28共刺激途径的协同或互补途径发挥作用。4-1BB/4-IBB配体的一些基本免疫功能仅得到了阐明,还需要进行大量研究以确定其在T细胞活化中的确切作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验